LAT and neoplasm: To investigate whether LAT1 elevation contributes to chemo-resistance in TNBC, we established an induced Dox-resistant in vivo PDX mouse model by treating mice implanted with human TNBC tumors with increasing doses of Doxorubicin over eight weeks, across four tumor passages.